title: Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.
abstract: Lipid A, the active moiety of LPS, exerts its effects through interaction with TLR4, triggering a signalling cascade that results in the release of pro-inflammatory cytokines. Eritoran is a lipid A analogue that competes with LPS for binding to TLR4; however, after intravenous administration, it undergoes a time-dependent deactivation as a consequence of binding to high-density lipoproteins (HDLs). The site of eritoran association with HDL remains unknown. Therefore the aim of this study was to determine if HDL-associated apolipoproteins A1, A2, serum amyloid A (SAA) and C1, inhibit the ability of eritoran to block LPS-induced TNF-α release from whole blood. Eritoran activity after LPS stimulation in human whole blood was assessed in the presence of reconstituted HDL (rHDL) containing different apos. In rHDL, the major apolipoproteins in both the healthy and septic state, A1 and SAA, caused a significant reduction in eritoran antagonistic activity and had a greater effect than minor apolipoproteins A2 and C1. Apolipoproteins associated with HDL are likely to facilitate eritoran deactivation. Apolipoproteins A1 and SAA should be of particular focus as they are the major apos found on HDL in both the healthy and septic state. Further evaluation of the physical association between apolipoproteins and eritoran should be explored.
authors.affiliation: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Jacklyn G
authors.initials: JG
authors.lastname: Fleischer
authors.forename: Dan
authors.initials: D
authors.lastname: Rossignol
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Francis
authors.forename: Teddy
authors.initials: T
authors.lastname: Chan
authors.forename: Melvyn
authors.initials: M
authors.lastname: Lynn
authors.forename: Kishor M
authors.initials: KM
authors.lastname: Wasan
mesh_terms: D016632:Apolipoprotein A-I / Q000737:chemistry / Q000378:metabolism; D016633:Apolipoprotein A-II / Q000737:chemistry / Q000378:metabolism; D001667:Binding, Competitive; D001773:Blood Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D004187:Disaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D008050:Lipid A / Q000037:antagonists & inhibitors*; D008075:Lipoproteins, HDL / Q000276:immunology*; D015394:Molecular Structure; D000685:Serum Amyloid A Protein / Q000378:metabolism; D013403:Sugar Phosphates / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D004187:Disaccharides; D008050:Lipid A; D008075:Lipoproteins, HDL; D000685:Serum Amyloid A Protein; D013403:Sugar Phosphates; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; C512420:eritoran